GLP-1survodutidediabetic kidney diseaseboehringer ingelheim

Journal paper asks whether survodutide protects kidneys in diabetic disease

The Diabetes, Obesity and Metabolism piece examines whether renal effects of the glucagon/GLP-1 dual agonist go beyond weight and blood pressure changes.

By Maren Holt · Senior Reporter, GLP-1

Oct 11 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01He and colleagues published an October 12 article in Diabetes, Obesity and Metabolism questioning whether survodutide offers renoprotection beyond its metabolic and haemodynamic effects in diabetic kidney disease.
02Kidney outcomes are a growing point of differentiation among incretin agents for clinicians managing patients with type 2 diabetes and chronic kidney disease.
03Only the title and citation are available; readers should check the full text for study design, population and whether any dedicated renal outcome data support the question posed.

From the source

Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?
Diabetes, obesity & metabolism · 2026 Oct 12 · He J et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42864267/